Daré Bioscience CEO Sabrina Martucci Johnson Honored on Forbes 2026 '50 Over 50: Innovation' List
Event summary
- Daré Bioscience CEO Sabrina Martucci Johnson named to Forbes 2026 '50 Over 50: Innovation' list.
- Daré Bioscience focuses exclusively on women's health, with a portfolio spanning contraception, sexual health, menopause, and infectious disease.
- Company's commercial products include DARE to PLAY™ Sildenafil Cream and Flora Sync LF5™, with Ovaprene® in pivotal Phase 3 clinical trials.
- Johnson's career spans scientific research, finance, operations, and public-company leadership in biotechnology and women’s reproductive healthcare.
The big picture
Daré Bioscience’s recognition on the Forbes list underscores the growing investor and industry interest in women’s health innovation. The company’s decade-long focus on this underserved market positions it uniquely as the healthcare sector increasingly acknowledges historical underinvestment in women’s health. Daré’s portfolio approach, spanning commercial products and developmental programs, aims to create multiple pathways to value creation, differentiating it from single-asset biotech firms.
What we're watching
- Portfolio Diversification
- Whether Daré Bioscience can sustain its multi-product strategy and transition from a clinical-stage biotech to a commercial women’s health company.
- Regulatory Pathways
- The pace at which Daré advances its products through regulatory approvals, particularly Ovaprene’s potential as the first FDA-approved monthly hormone-free intravaginal contraceptive.
- Market Acceptance
- How the market responds to Daré’s commercial offerings and whether they gain significant traction in the women’s health sector.
Related topics